[go: up one dir, main page]

WO2009041789A3 - Novel 3-chloro-5-substituted-quinoxaline-2-amine derivatives and pharmaceutically acceptable salt thereof, method for preparation, therapeutic agent for inflammatory disease induced by spc activity containing 3-chloro-5-substituted-quinoxaline-2-amine derivatives as an effective ingredient - Google Patents

Novel 3-chloro-5-substituted-quinoxaline-2-amine derivatives and pharmaceutically acceptable salt thereof, method for preparation, therapeutic agent for inflammatory disease induced by spc activity containing 3-chloro-5-substituted-quinoxaline-2-amine derivatives as an effective ingredient Download PDF

Info

Publication number
WO2009041789A3
WO2009041789A3 PCT/KR2008/005725 KR2008005725W WO2009041789A3 WO 2009041789 A3 WO2009041789 A3 WO 2009041789A3 KR 2008005725 W KR2008005725 W KR 2008005725W WO 2009041789 A3 WO2009041789 A3 WO 2009041789A3
Authority
WO
WIPO (PCT)
Prior art keywords
chloro
quinoxaline
substituted
amine derivatives
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2008/005725
Other languages
French (fr)
Other versions
WO2009041789A2 (en
Inventor
Young-Dae Gong
Heeyeong Cho
Moon-Kook Jeon
Taeho Lee
Gildon Choi
Jae-Yang Kong
Woo-Kyu Park
Soon-Hee Hwang
Jung Ju Kim
Chang-Hoon Lee
Jaeyoung Ko
Minsoo Noh
Eun Sil Han
Hyuk Kim
Jun-Won Yun
Joo Hyun Moh
Do Hoon Kim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Korea Research Institute of Chemical Technology KRICT
Amorepacific Corp
Original Assignee
Korea Research Institute of Chemical Technology KRICT
Amorepacific Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Korea Research Institute of Chemical Technology KRICT, Amorepacific Corp filed Critical Korea Research Institute of Chemical Technology KRICT
Publication of WO2009041789A2 publication Critical patent/WO2009041789A2/en
Publication of WO2009041789A3 publication Critical patent/WO2009041789A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Provided are a 3-chloro-5-substiuted-quinoxalin-2-amine derivative represented by the following Chemical Formula 1, a pharmaceutically acceptable salt thereof, a method for preparation thereof, and a use thereof as an effective ingredient in a therapeutic agent for inflammatory disease induced by activity of sphingosyl phosphorylcholine (SPC) receptor. The 3-chloro-5-substiuted-quinoxalin-2-amine derivative of the present invention has been confirmed to have superior inhibition activity against SPC receptor in an animal experiment using human-derived endothelial cells and mice. Thus, a therapeutic agent for inflammatory disease containing the 3- chloro-5-substiuted-quinoxalin-2-amine derivative or a pharmaceutically acceptable salt thereof as an effective ingredient may be useful for treating inflammation, itching or skin infection associated with atopic dermatitis or other disease induced by activity of SPC receptor.
PCT/KR2008/005725 2007-09-27 2008-09-26 Novel 3-chloro-5-substituted-quinoxaline-2-amine derivatives and pharmaceutically acceptable salt thereof, method for preparation, therapeutic agent for inflammatory disease induced by spc activity containing 3-chloro-5-substituted-quinoxaline-2-amine derivatives as an effective ingredient Ceased WO2009041789A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020070097554A KR100916716B1 (en) 2007-09-27 2007-09-27 Novel 3-chloro-5-substituted-quinoxaline-2-amine derivatives and pharmaceutically acceptable salt thereof, method for preparation, therapeutic agent for antiinflammatory disease induced by spc activity containing 3-chloro-5-substituted-quinoxaline-2-amine derivatives as an effective ingredient
KR10-2007-0097554 2007-09-27

Publications (2)

Publication Number Publication Date
WO2009041789A2 WO2009041789A2 (en) 2009-04-02
WO2009041789A3 true WO2009041789A3 (en) 2009-05-14

Family

ID=40512033

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2008/005725 Ceased WO2009041789A2 (en) 2007-09-27 2008-09-26 Novel 3-chloro-5-substituted-quinoxaline-2-amine derivatives and pharmaceutically acceptable salt thereof, method for preparation, therapeutic agent for inflammatory disease induced by spc activity containing 3-chloro-5-substituted-quinoxaline-2-amine derivatives as an effective ingredient

Country Status (2)

Country Link
KR (1) KR100916716B1 (en)
WO (1) WO2009041789A2 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004054584A1 (en) * 2002-12-13 2004-07-01 Merck & Co., Inc. Novel quinoxalinone derivatives as bradykinin b1 antagonists
US20050020600A1 (en) * 2003-07-23 2005-01-27 Scherer Warren J. Methods of treating cutaneous flushing using selective alpha-2-adrenergic receptor agonists
US20050020590A1 (en) * 2003-07-25 2005-01-27 Hengyuan Lang P-38 kinase inhibitors

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2003062234A1 (en) * 2002-01-23 2005-05-19 山之内製薬株式会社 Quinoxaline compounds

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004054584A1 (en) * 2002-12-13 2004-07-01 Merck & Co., Inc. Novel quinoxalinone derivatives as bradykinin b1 antagonists
US20050020600A1 (en) * 2003-07-23 2005-01-27 Scherer Warren J. Methods of treating cutaneous flushing using selective alpha-2-adrenergic receptor agonists
US20050020590A1 (en) * 2003-07-25 2005-01-27 Hengyuan Lang P-38 kinase inhibitors

Also Published As

Publication number Publication date
KR20090032373A (en) 2009-04-01
KR100916716B1 (en) 2009-09-10
WO2009041789A2 (en) 2009-04-02

Similar Documents

Publication Publication Date Title
TW200716648A (en) Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia
WO2010098600A3 (en) Substituted azole derivatives, pharmaceutical composition containing the derivatives, and method for treating parkinson's disease using the same
WO2009106980A3 (en) Indazole derivatives
PH12013501594A1 (en) Substituted indazole derivatives active as kinase inhibitors
TW200738729A (en) Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia
NO20073719L (en) Chemical connections
NO20080408L (en) Azaindazole Compounds and Their Use
WO2011027249A3 (en) Benzimidazole derivatives
NO20084872L (en) 2-pyridone derivatives for the treatment of disease or conditions where inhibition of neutrophil elastase activity is beneficial
ATE557015T1 (en) 3,4-DIARYLPYRAZOLES AS PROTEIN KINASE INHIBITORS
NO20071246L (en) Quinazolinone derivatives and their use as B-RAF inhibitors.
MX2009006401A (en) Indazole derivatives as kinase inhibitors for the treatment of cancer.
NO20070199L (en) Substituted quinazolones as anti-cancer agents
NO20084496L (en) Pyridyl and pyrimidinyl substituted pyrrole, thiophene and furan derivatives as kinase inhibitors
WO2009071480A3 (en) Substituted dihydropteridin-6-one derivatives, process for their preparation and their use as kinase inhibitors
NO20084202L (en) 4-Anilinoquinoline-3-carboxamides as CSF-1R Kinase Inhibitors
TW200833693A (en) Substituted pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors
WO2009030952A3 (en) Phenylcarboxamide derivatives as inhibitors and effectors of the hedgehog pathway
WO2007071963A3 (en) Quinazoline derivatives, process for their preparation and their use as anti-cancer agents
NO20083058L (en) Cyclohexylsulfonamide derivatives with H3 receptor activity
MX2014005075A (en) Meglumine salt formulations of 1-(5,6-dichloro-1h-benzo[d]imidazo l-2-yl)-1h-pyrazole-4-carboxylic acid.
MX2010009462A (en) Indazole derivatives.
ATE496918T1 (en) 5-PHENYL-6-PYRIDINE-4-YL-1,3-DIHYDRO-2H-IMIDAZOÄ4, - BÜPYRIDINE-2-ONE DERIVATIVES SUITABLE AS A2B ADENOSINE RECEPTOR ANTAGONISTS
CL2009001267A1 (en) Compounds derived from nitrogenous tricycles, with antibacterial activity; preparation procedure; pharmaceutical composition comprising them; for the treatment of tuberculosis.
WO2009038412A3 (en) Beta-secretase inhibiting compounds

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08832998

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08832998

Country of ref document: EP

Kind code of ref document: A2